» Articles » PMID: 31213025

Paclitaxel-Loaded Silk Fibroin Nanoparticles: Method Validation by UHPLC-MS/MS to Assess an Exogenous Approach to Load Cytotoxic Drugs

Overview
Journal Pharmaceutics
Publisher MDPI
Date 2019 Jun 20
PMID 31213025
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

The aim of this work was to load an anticancer drug, paclitaxel (PTX), on Silk Fibroin Nanoparticles (SFNs) by using an exogenous approach. SFNs were produced, freeze-dried and then loaded with PTX. An exogenous method allowed us to reduce both drug loss and environmental impact. In order to quantify PTX loaded in SFNs, a simple and reliable method using reversed phase liquid chromatography coupled to tandem mass spectrometry (rp-UHPLC-MS/MS) was developed. This methodology was validated by the determination of spiked QC samples in three consecutive days. Good accuracy and precision of the method were obtained, while the intra-day and inter-day precisions were less than 10.3%. For PTX, the limit of quantitation (LOQ) was 5.0 ng/mL. Recovery from the matrix (SFNs-PTX pellets) was calculated (81.2% at LOQ value) as PTX was entrapped in a new matrix like the polymer silk fibroin-based. This method was successfully applied to determine the encapsulation efficiency (1.00 ± 0.19%) and the nanoparticle loading (0.12 ± 0.02% /). The in vitro anticancer activity of SFNs-PTX was tested against CFPAC-1 cancer cells; results demonstrated a very high cytotoxic activity of SFNs-PTX, with a dose dependent inhibition of CFPAC-1 proliferation, confirmed by the IC50 value of 3450 ± 750 ng/mL.

Citing Articles

Doxycycline-integrated silk fibroin hydrogel: preparation, characterizations, and antimicrobial assessment for biomedical applications.

Ealla K, Durga C, Sahu V, Kumari N, Venkatesan J, Veeraraghavan V BMC Oral Health. 2025; 25(1):177.

PMID: 39893416 PMC: 11787760. DOI: 10.1186/s12903-025-05568-4.


Matrix-Assisted Laser Desorption and Electrospray Ionization Tandem Mass Spectrometry of Microbial and Synthetic Biodegradable Polymers.

Rizzarelli P, Rapisarda M Polymers (Basel). 2023; 15(10).

PMID: 37242931 PMC: 10222159. DOI: 10.3390/polym15102356.


Systemic and Local Silk-Based Drug Delivery Systems for Cancer Therapy.

Florczak A, Deptuch T, Kucharczyk K, Dams-Kozlowska H Cancers (Basel). 2021; 13(21).

PMID: 34771557 PMC: 8582423. DOI: 10.3390/cancers13215389.


Biomaterials for Soft Tissue Repair and Regeneration: A Focus on Italian Research in the Field.

Bonferoni M, Caramella C, Catenacci L, Conti B, Dorati R, Ferrari F Pharmaceutics. 2021; 13(9).

PMID: 34575417 PMC: 8471088. DOI: 10.3390/pharmaceutics13091341.


Enhanced Cytotoxic Activity of Docetaxel-Loaded Silk Fibroin Nanoparticles against Breast Cancer Cells.

Al Saqr A, Wani S, Gangadharappa H, Aldawsari M, Khafagy E, Lila A Polymers (Basel). 2021; 13(9).

PMID: 33925581 PMC: 8123888. DOI: 10.3390/polym13091416.


References
1.
Zhao Z, Li Y, Xie M . Silk fibroin-based nanoparticles for drug delivery. Int J Mol Sci. 2015; 16(3):4880-903. PMC: 4394455. DOI: 10.3390/ijms16034880. View

2.
Jimenez-Amezcua I, Carmona F, Romero-Garcia I, Quiros M, Cenis J, Lozano-Perez A . Silk fibroin nanoparticles as biocompatible nanocarriers of a novel light-responsive CO-prodrug. Dalton Trans. 2018; 47(31):10434-10438. DOI: 10.1039/c8dt02125b. View

3.
Li H, Tian J, Wu A, Wang J, Ge C, Sun Z . Self-assembled silk fibroin nanoparticles loaded with binary drugs in the treatment of breast carcinoma. Int J Nanomedicine. 2016; 11:4373-80. PMC: 5015876. DOI: 10.2147/IJN.S108633. View

4.
Zhang W, Dutschman G, Li X, Cheng Y . Quantitation of paclitaxel and its two major metabolites using a liquid chromatography-electrospray ionization tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2011; 879(22):2018-22. DOI: 10.1016/j.jchromb.2011.05.024. View

5.
Mwangi T, Bowles R, Tainter D, Bell R, Kaplan D, Setton L . Synthesis and characterization of silk fibroin microparticles for intra-articular drug delivery. Int J Pharm. 2015; 485(1-2):7-14. PMC: 4422162. DOI: 10.1016/j.ijpharm.2015.02.059. View